miR-106b-5p as a Central Regulator of Cancer Progression and Chemotherapy-Induced Cardiotoxicity: From Molecular Mechanisms to Clinical Translation
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262010002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Maria Del Carmen Asensio Lopez und 7 weiteren Autor:innen. Beteiligte Einrichtung: R&D Department, Biocardio S.L., El Palmar, 30120 Murcia, Spain. Hauptthemen laut MEDLINE: MicroRNAs, Cardiotoxicity, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ayudas a la realización de proyectos para el desarrollo de investigación científica y técnica por grupos competitivos 2022.
Themen: Onkologische Pflege
Abstract (Originalsprache)
MicroRNAs (miRNAs) are critical regulators of gene expression in cancer biology and cardiovascular disease. miR-106b-5p, a member of the miR-106b-25 cluster, has been widely studied for its oncogenic activity in various malignancies. However, its role as a direct molecular driver of anthracycline-induced cardiotoxicity has only recently been uncovered. This finding highlights new therapeutic possibilities at the intersection of oncology and cardiovascular medicine. This review outlines the dual role of miR-106b-5p as a key modulator in both tumor progression and chemotherapy-induced cardiac dysfunction. miR-106b-5p is upregulated in numerous cancers—including breast, prostate, lung, gastric, colorectal, hepatocellular, and esophageal—and promotes tumorigenesis via suppression of tumor suppressors such as PTEN, BTG3, p21, and SMAD7, leading to activation of oncogenic pathways like PI3K/AKT and TGF-β. Importantly, we present the first evidence that miR-106b-5p is significantly upregulated in the myocardium in response to doxorubicin treatment, where it drives left ventricular dysfunction by targeting PR55α, a key regulator of PP2A activity. This pathway results in cytoplasmic HDAC4 accumulation, aberrant activation of the YY1 transcription factor, and upregulation of sST2, a biomarker linked to adverse cardiac remodeling and poor prognosis. In response, we developed AM106, a novel locked nucleic acid antagomir that silences miR-106 b-5p. Preclinical studies demonstrate that AM106 restores PR55α/PP2A activity, reduces sST2 expression, and prevents structural and functional cardiac damage without compromising anti-tumor efficacy. In parallel, artificial intelligence (AI) tools could be leveraged in the future—based on established AI applications in miRNA cancer research—to accelerate the identification of miR-106b-5p-related biomarkers and guide personalized therapy selection. Our findings position miR-106b-5p as a previously unrecognized molecular bridge between cancer and doxorubicin-induced cardiotoxicity. The development of the AM106 antagomir represents a promising approach with potential clinical applicability in cardio-oncology, offering dual benefits: tumor control and cardioprotection. Coupling this innovation with AI-driven analysis of patient data may enable precision risk stratification, early intervention, and improved outcomes. miR-106b-5p thus emerges as a central therapeutic target and biomarker candidate for transforming the clinical management of cancer patients at risk for heart failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- R&D Department, Biocardio S.L., El Palmar, 30120 Murcia, Spain.
- Instituto Murciano de Investigación Biosanitaria (IMIB) Pascual Parrilla, University of Murcia, 30120 Murcia, Spain.
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain.
- Servicio de Oncología Médica, Hospital Clínico Universitario Virgen de la Arrixaca, 30120 Murcia, Spain.
- Heart Failure Unit, Cardiology Department, Virgen de la Arrixaca Hospital, School of Medicine, University of Murcia, 30120 Murcia, Spain.
- Cardiology Department, Hospital Virgen de la Arrixaca, IMIB-Pascual Parrilla, University of Murcia, El Palmar, 30120 Murcia, Spain.
ORCID-Profile: Maria Del Carmen Asensio Lopez, Francisco Jose Bastida Nicolas, Jose Luis Alonso-Romero, Cesar Caro-Martinez, Domingo Pascual Figal, Antonio Lax
Förderung
- Ayudas a la realización de proyectos para el desarrollo de investigación científica y técnica por grupos competitivos 2022
Zitieren
APA
Asensio Lopez, M. D. C., Ruiz Ballester, M., Bastida Nicolas, F. J., Soler Pardo, F., Alonso-Romero, J. L., Caro-Martinez, C., Pascual Figal, D., & Lax, A. (2025). miR-106b-5p as a Central Regulator of Cancer Progression and Chemotherapy-Induced Cardiotoxicity: From Molecular Mechanisms to Clinical Translation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262010002
Vancouver
Asensio Lopez MDC, Ruiz Ballester M, Bastida Nicolas FJ, Soler Pardo F, Alonso-Romero JL, Caro-Martinez C, et al. miR-106b-5p as a Central Regulator of Cancer Progression and Chemotherapy-Induced Cardiotoxicity: From Molecular Mechanisms to Clinical Translation. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262010002
BibTeX
@article{AsensioLopez2025,
author = {Asensio Lopez, Maria Del Carmen and Ruiz Ballester, Miriam and Bastida Nicolas, Francisco Jose and Soler Pardo, Fernando and Alonso-Romero, Jose Luis and Caro-Martinez, Cesar and Pascual Figal, Domingo and Lax, Antonio},
title = {miR-106b-5p as a Central Regulator of Cancer Progression and Chemotherapy-Induced Cardiotoxicity: From Molecular Mechanisms to Clinical Translation},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262010002}
}
EUVIMED